From the Research
Sublingual sermorelin is not recommended as an effective method of administration. Sermorelin, a growth hormone-releasing hormone (GHRH) analog, is typically administered via subcutaneous injection rather than sublingually. The standard dosage for sermorelin is 100-500 mcg injected subcutaneously once daily, usually before bedtime to align with the body's natural growth hormone pulse. Sublingual administration is problematic because sermorelin is a peptide that undergoes significant first-pass metabolism and degradation in the digestive tract, making it poorly absorbed through mucous membranes. The molecular structure of sermorelin (a 29-amino acid peptide) makes it unsuitable for effective sublingual absorption, as peptides generally have poor bioavailability through this route.
Some key points to consider:
- Sermorelin is effective in promoting growth in some prepubertal children with idiopathic growth hormone deficiency when administered subcutaneously 1.
- The efficacy and safety of sermorelin have been demonstrated in several studies, including a multicenter, open-label study that showed significant increases in height velocity in growth hormone-deficient children 2.
- If you're interested in sermorelin therapy, consult with a healthcare provider who can prescribe the appropriate injectable form and monitor your response.
- Side effects may include injection site reactions, headache, dizziness, and flushing.
- Sermorelin is used to stimulate natural growth hormone production and may be prescribed for growth hormone deficiency or anti-aging purposes, though its off-label anti-aging use remains controversial.
It's essential to note that the provided evidence does not support the use of sublingual sermorelin, and the most effective and recommended method of administration is subcutaneous injection. Therefore, sublingual sermorelin supplementation is not a recommended treatment option.